Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion?

Clinical and Experimental Ophthalmology

Volumn 34, Issue 4, 2006, Pages 305-311

  Gumus, Koray ^a   Kadayifcilar, Sibel ^a   Eldem, Bora ^a   Saracbasi, Osman ^a   Ozcebe, Osman ^a   Dundar, Semra ^a   Kirazli, Serafettin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Branch retinal vein occlusion; Central retinal vein occlusion; Risk factor; Soluble endothelial protein C receptor; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ADENINE; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; FIBRINOGEN; GENE PRODUCT; GLUCOSE; GUANINE; HOMOCYSTEINE; LIPID; LIPOPROTEIN A; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; GLAUCOMA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTEIN BLOOD LEVEL; RETINA VEIN OCCLUSION; RISK FACTOR; VEIN THROMBOSIS;

ADULT; AGED; ANTIGENS, CD; FACTOR VIII; FEMALE; GLAUCOMA; HOMOCYSTEINE; HUMANS; HYPERTENSION; LIPOPROTEIN(A); MALE; MIDDLE AGED; ODDS RATIO; RECEPTORS, CELL SURFACE; RETINAL VEIN OCCLUSION; RISK FACTORS; SOLUBILITY; VENOUS THROMBOSIS;

EID: 33746519951     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2006.01212.x     Document Type: Article

References (23)

1. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-54.
2. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.
3. The Eye Disease Case-Control Study Group. Risk factors for branch vein occlusion. Am J Ophthalmol 1993; 116: 286-96.
4. Williamson TH, Rumley A, Lowe GDO. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: A population controlled study. Br J Ophthalmol 1996; 80: 203-8.
5. Greiner K, Hafner G, Dick B, Peetz D, Prellwitz W, Pfeiffer N. Retinal vein occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999; 128: 69-74.
6. Hansen L, Kristensen HL, Bek T, Ingerslev J. Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand 2000; 78: 523-6.
7. Boyd S, Owens D, Gin T et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001; 85: 1313-15.
8. Bandello F, D'Angelo SV, Parlavecchia M et al. Hypercoagulability and high lipoprotein (a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994; 72: 39-43.
9. Kadayifçilar S, Özatli D, Özcebe O, Sener EC. Is activated factor VII associated with retinal vein occlusion? Br J Ophthalmol 2001; 85: 1174-8.
10. Esmon CT, Ding W, Yasuhiro K et al. The protein C pathway: New insights. Thromb Haemost 1997; 78: 70-4.
11. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-91.
12. Fukudome K, Kurosawa S, Stearns-Kurosawa DJ, He X, Rezaie AR, Esmon CT. The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 1996; 271: 17491-8.
13. Laszik Z, Mitro A, Taylor FB, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for control of the protein C pathway. Circulation 1997; 96: 3633-40.
14. Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 1997; 100: 411-18.
15. Liaw PC, Neuenchwander PF, Smirnov MD, Esmon CT. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem 2000; 275: 5447-52.
16. Bhagat N, Goldberg MF, Gascon P, Bell W, Haberman J, Zarbin MA. Central retinal vein occlusion: Review of management. Eur J Ophthalmol 1999; 9: 165-80.
17. Xu J, Qu D, Esmon NL, Esmon CT. Metalloproteolytic release of endothelial protein C receptor. J Biol Chem 2000; 275: 6038-44.
18. Stearns-Kurosawa D, Swindle K, D'Angelo A et al. Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood 2002; 99: 526-30.
19. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della Valle P, Esmon CT. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998; 91: 725-7.
20. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004; 103: 1311-18.
21. Uitte de Willige S, Van Marion V, Rosendaal FR, Vos HL, de Visser MCH, Bertina RM. Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost 2004; 2: 1305-10.
22. Medina P, Navarro S, Estelles A et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb Haemost 2004; 91: 905-11.
23. Stearns-Kurosawa DJ, Burgin C, Parker D, Comp P, Kurosawa S. Bimodal distribution of soluble endothelial protein C receptor levels in healthy populations [Letter]. J Thromb Haemost 2003; 1: 855-6.